Olaparib effective against BRCA2-mutated prostate cancer

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a phase II clinical trial of 51 patients conducted at the Johns Hopkins Kimmel Cancer Center and three other sites.


http://dlvr.it/TCGqDP

Comments

Post a Comment

Popular posts from this blog

GLP-1 Drugs Before Bariatric Surgery Can Help People With Extreme Obesity

Image
A new study looked at the impact of taking GLP-1 drugs before bariatric surgery. Halfpoint/Getty Images * New research finds that using GLP-1 drugs like Ozempic before bariatric surgery can help improve the health of people with extreme obesity. * Extreme obesity is defined as having a body mass index (BMI) of 70 or more. * In 2022, there were nearly 280,000 metabolic and bariatric surgeries in the United States. People with extreme obesity can reduce their risk of complications from bariatric or metabolic surgery by taking GLP-1 drugs before the procedures, according to a study presented over the weekend at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2024 Annual Scientific Meeting. The results of the study haven’t yet been published in a peer-reviewed scientific journal. Extreme obesity, which is defined as having a body mass index (BMI) of 70 or more, presents patients and doctors with complications during and after weight-loss surgery c
Read more

Diagnostic stewardship approach to C. diff reduces unnecessary testing

Image
A new study published today in the American Journal of Infection Control (AJIC) describes the outcome of a new approach to testing for Clostridioides difficile (C. diff), guided by the principles of diagnostic stewardship. At Memorial Health care System in Hollywood, Fla., revised rules for when C. diff tests could be ordered helped to reduce inappropriate testing by 20%, which in turn can help rein in the overtreatment of patients. Read More
Read more